DepYmed is a disease therapeutic development company that develops potent inhibitors of the enzyme PTP1B.
DepYmed has raised $1.1M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in March 2024.
DepYmed's investors include Accelerate New York Seed Fund, the Long Island Emerging technologies Fund (LIETF), Topspin Fund, Accelerate Long Island.
DepYmed is headquartered in Farmingdale, United States.
DepYmed is a disease therapeutic development company that develops potent inhibitors of the enzyme PTP1B.
DepYmed is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"DepYmed — Funding & Investors." VCBacked, March 11, 2024, https://www.vcbacked.co/company/depymed. Accessed July 26, 2026.
VCBacked. (2024). DepYmed — Funding & Investors. Retrieved July 26, 2026, from https://www.vcbacked.co/company/depymed
{{cite web |title=DepYmed — Funding & Investors |url=https://www.vcbacked.co/company/depymed |website=VCBacked |access-date=July 26, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated